Peptide receptors and pathways glossary

Peptide research compounds interact with specific cell-surface receptors and intracellular signalling pathways that have been characterised in extensive molecular pharmacology literature. Understanding the receptor targets and downstream signalling cascades of the peptides in a research catalog is foundational for designing meaningful in vitro and animal-model experiments, interpreting results, and selecting appropriate model systems. For research laboratories sourcing material from originlabsresearch.com, this glossary covers the major receptor families and signalling pathways relevant to the catalog, including growth hormone releasing hormone receptors, growth hormone secretagogue receptors, melanocortin receptors, incretin receptors, and the principal intracellular signal transduction cascades that propagate the activation signal from the cell surface to downstream effectors. The terminology in this glossary is drawn from published molecular pharmacology and biochemistry literature and reflects standard usage in current research. The glossary is presented in sections by receptor or pathway family to facilitate reference use during protocol design. This guide is supplied for research purposes only and does not constitute medical, clinical, or veterinary advice. Research personnel using catalog peptides in laboratory protocols are encouraged to consult the primary literature for the specific peptide and receptor of interest before designing experiments, since the breadth and depth of the published literature varies substantially across the catalog and is updated continuously as new in vitro and preclinical studies are published.

GHRH-R and GHS-R1a, the two pituitary growth hormone secretagogue receptors

GHRH-R is the growth hormone releasing hormone receptor, a class B G-protein-coupled receptor expressed predominantly on somatotroph cells of the anterior pituitary gland. The receptor binds endogenous growth hormone releasing hormone, a 44-amino acid hypothalamic peptide, and synthetic analogs including sermorelin, CJC-1295, and tesamorelin. Activation of GHRH-R triggers coupling to Gs proteins, which in turn activate adenylyl cyclase, raising intracellular cyclic AMP and activating protein kinase A. The cAMP-PKA signal converges on the transcription factor CREB to drive transcription of the growth hormone gene and to promote secretion of stored growth hormone from secretory granules in cell-culture and animal-model systems. GHRH-R has been studied extensively in research contexts spanning growth hormone deficiency models, ageing of the somatotropic axis, and the pharmacology of synthetic GHRH analogs. GHS-R1a is the growth hormone secretagogue receptor type 1a, a class A G-protein-coupled receptor expressed in the pituitary, hypothalamus, and several peripheral tissues. The receptor binds endogenous ghrelin, the acylated stomach-derived peptide, and synthetic agonists including ipamorelin, hexarelin, ibutamoren, and the broader family of growth hormone secretagogues. Activation of GHS-R1a couples primarily to Gq proteins, activating phospholipase C and raising intracellular calcium through the inositol trisphosphate pathway. The receptor exhibits constitutive activity in the absence of ligand and has been studied in relation to growth hormone release, appetite regulation, and energy homeostasis in published animal-model literature. The combination of GHRH and a GHS-R1a agonist has been studied in preclinical pharmacology as producing synergistic effects on growth hormone release compared to either agent alone.

Melanocortin receptors MC1R, MC3R, MC4R, and MC5R

The melanocortin receptor family comprises five class A G-protein-coupled receptors that bind peptides derived from proopiomelanocortin and synthetic melanocortin analogs. MC1R is expressed predominantly on melanocytes and is the receptor responsible for the pigmentation response to alpha-melanocyte stimulating hormone. Activation of MC1R couples to Gs proteins, raising cyclic AMP and activating the microphthalmia-associated transcription factor pathway that drives melanin synthesis. MC1R has been studied in research models of pigmentation biology, with synthetic agonists including alpha-MSH analogs and the melanotan family. MC3R is expressed in the hypothalamus and several peripheral tissues and has been studied in relation to energy homeostasis and inflammation. MC4R is expressed predominantly in the hypothalamus and has been studied extensively in the context of appetite regulation and body weight in rodent models, with both endogenous melanocortin peptides and synthetic agonists including PT-141 acting as research tools. MC4R activation couples to Gs proteins and the cAMP-PKA cascade. MC5R is expressed in exocrine glands and several peripheral tissues with less characterised functional roles. The melanotan II peptide is a non-selective melanocortin receptor agonist that has been investigated as a research tool in studies of pigmentation, energy balance, and sexual behaviour in animal models. PT-141, also known as bremelanotide, is a related cyclic heptapeptide with relative selectivity for MC4R and MC3R that has been investigated in preclinical research models of sexual behaviour. The melanocortin family as a whole has been described as a convergence point for pigmentation, energy balance, inflammation, and behavioural research, and the selectivity profile of any particular peptide across the five receptor subtypes is a relevant parameter in experimental design.

GLP-1R, GIPR, and GCGR, the incretin and glucagon receptor family

The incretin and glucagon receptor family comprises three class B G-protein-coupled receptors that mediate the signalling effects of peptides involved in glucose homeostasis, energy balance, and gastrointestinal motility in published animal-model literature. GLP-1R is the receptor for glucagon-like peptide 1, an endogenous incretin hormone secreted from intestinal L-cells in response to nutrient ingestion. The receptor is expressed in pancreatic beta cells, where activation promotes glucose-dependent insulin secretion, and in the central nervous system, where activation has been studied in relation to satiety in preclinical models. Synthetic GLP-1R agonists studied in research include semaglutide, liraglutide, and dulaglutide. GIPR is the receptor for glucose-dependent insulinotropic polypeptide, the second major incretin hormone, secreted from intestinal K-cells in response to nutrient ingestion. The receptor is expressed in pancreatic beta cells where activation promotes glucose-dependent insulin secretion, and has been characterised in relation to insulin response and adipose tissue signalling in animal-model studies. GCGR is the glucagon receptor, expressed predominantly in hepatocytes where activation promotes hepatic glucose output and lipolysis. The combination agonists tirzepatide, which activates GIPR and GLP-1R, and retatrutide, which activates GIPR, GLP-1R, and GCGR, have been investigated as triple and dual agonists with engineered receptor selectivity profiles. Activation of all three receptors couples primarily to Gs proteins and the cAMP-PKA cascade, with additional signalling through beta-arrestin recruitment, Gq coupling, and downstream effects on MAP kinase cascades. The relative receptor selectivity of an incretin-family peptide, the bias toward G-protein versus beta-arrestin signalling, and the duration of receptor occupancy are all parameters that have been studied in detail for the engineered compounds in this class.

Gs, Gq, and Gi protein coupling and downstream cascades

G-protein-coupled receptors transduce extracellular peptide binding into intracellular signals through heterotrimeric G proteins, of which three principal families are most relevant to peptide pharmacology. Gs proteins activate adenylyl cyclase, raising intracellular cyclic AMP and activating protein kinase A. The cAMP-PKA cascade has been studied as a major intracellular signal transduction pathway that phosphorylates numerous substrate proteins and converges on the transcription factor CREB to regulate gene expression in cell-culture and animal-model systems. Many peptide receptors including GHRH-R, MC4R, GLP-1R, GIPR, and GCGR couple primarily through Gs. Gq proteins activate phospholipase C beta, which cleaves phosphatidylinositol 4,5-bisphosphate into inositol 1,4,5-trisphosphate and diacylglycerol. The IP3 mobilises calcium from intracellular stores while diacylglycerol activates protein kinase C, and the calcium-PKC cascade has been studied as the principal signalling output of Gq-coupled receptors. GHS-R1a is a prominent example of a peptide receptor coupling to Gq. Gi proteins inhibit adenylyl cyclase, lowering intracellular cyclic AMP and providing a counter-regulatory signal to Gs activation. Several peptide receptors couple to Gi or exhibit dual coupling that depends on cell type and ligand. Beta-arrestin recruitment is an additional signalling axis that occurs downstream of GPCR activation and has been studied as a mediator of receptor desensitisation, internalisation, and a distinct set of signalling outputs including MAP kinase activation. The bias of a peptide ligand for G-protein versus beta-arrestin signalling at a given receptor is a parameter that has been studied in detail for several engineered peptide agonists and can be the basis for distinct functional profiles of agonists at the same receptor.

Other relevant receptors: ACE, FPR2, somatostatin, and tissue repair pathways

Several peptide receptors fall outside the major families discussed above but are relevant to specific research compounds in the catalog. The angiotensin-converting enzyme system has been studied in relation to peptides such as TB-500 indirectly, where the broader tissue repair signalling network engages multiple pathways. FPR2, the formyl peptide receptor 2, has been studied as a target of certain pro-resolution peptide signals and has been referenced in the context of soft tissue repair research in rodent models. Somatostatin receptors are five GPCR subtypes that bind endogenous somatostatin and analogs and provide a counter-regulatory signal to growth hormone secretagogue activity at the pituitary level. Various tissue repair peptides have been investigated for activity through pathways that are not yet fully characterised at the receptor level, with BPC-157 being the most prominent example. Published animal-model research on BPC-157 has referenced involvement of nitric oxide signalling, growth factor receptor activation including VEGFR, and modulation of the dopaminergic and serotonergic systems, but the primary high-affinity receptor for BPC-157 has not been definitively identified in the published literature. Thymosin beta-4 and its truncated active fragment TB-500 have been investigated as binding to G-actin to regulate cytoskeletal dynamics, and as engaging multiple downstream signalling pathways relevant to tissue repair. The GHK tripeptide and its copper complex GHK-Cu have been studied in relation to copper binding and downstream effects on extracellular matrix remodelling genes in fibroblast culture systems. MOTS-c, a mitochondrial-derived peptide, has been investigated in relation to AMPK pathway activation in rodent metabolic models. The diversity of mechanism across the peptide catalog reflects the breadth of biological signalling systems engaged by short bioactive peptides, and research personnel should consult the primary literature for the specific peptide of interest when planning experiments that depend on precise mechanistic understanding.

References

1. [1] Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, et al (1996). A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. PMID 8688086
2. [2] Mountjoy KG, Robbins LS, Mortrud MT, Cone RD (1992). The cloning of a family of genes that encode the melanocortin receptors. Science. PMID 1325670
3. [3] Drucker DJ (2018). Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabolism. PMID 29320708
4. [4] Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, et al (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for type 2 diabetes. Molecular Metabolism. PMID 30473097
5. [5] Jastreboff AM, Kaplan LM, Frias JP, Wu Q, Du Y, Gurbuz S, et al (2023). Triple-hormone-receptor agonist retatrutide for obesity. New England Journal of Medicine. PMID 37366315

Frequently asked questions